CAR-37 and previous treatments by patient
| Patient no. . | Age/sex . | Disease . | Previous therapies . | Baseline BM involvement . | CAR37 dose level (actual no. received) . |
|---|---|---|---|---|---|
| 1 | 61/F | Double-hit HGBCL | R-EPOCH, IT MTX/cytarabine, HD-MTX, R/Gem/Ox, cy/flu/tisagenlecleucel (Kymriah), XRT, and pembrolizumab | No | DL1 (120 e6) frozen |
| 3 | 70/M | CTCL | Photopheresis, alemtuzumab (Campath), total skin electron beam radiation, flu/cy/TBI/MMF-RIC, haplo PBSCT, brentuximab, DLI, and XRT | No | DL1 (19 e6) fresh |
| 4 | 63/F | Double-hit HGBCL | DA-EPOCH-R, R-DHAP, and cy/flu/axicabtagene ciloleucel (Yescarta) | No | DL1 (229 e6) fresh |
| 5 | 35/F | Classical Hodgkin | ABVD, brentuximab, GDP, ICE, nivolumab, and everolimus | No | DL1 (120 e6) frozen |
| 7 | 46/F | NK/T-cell lymphoma, nasal type | Dex/etoposide/ifosfamide/carboplatin; XRT to soft palate and LN; pembrolizumab; ulixertinib | Yes | DL −1 (30 e6) frozen |
| Patient no. . | Age/sex . | Disease . | Previous therapies . | Baseline BM involvement . | CAR37 dose level (actual no. received) . |
|---|---|---|---|---|---|
| 1 | 61/F | Double-hit HGBCL | R-EPOCH, IT MTX/cytarabine, HD-MTX, R/Gem/Ox, cy/flu/tisagenlecleucel (Kymriah), XRT, and pembrolizumab | No | DL1 (120 e6) frozen |
| 3 | 70/M | CTCL | Photopheresis, alemtuzumab (Campath), total skin electron beam radiation, flu/cy/TBI/MMF-RIC, haplo PBSCT, brentuximab, DLI, and XRT | No | DL1 (19 e6) fresh |
| 4 | 63/F | Double-hit HGBCL | DA-EPOCH-R, R-DHAP, and cy/flu/axicabtagene ciloleucel (Yescarta) | No | DL1 (229 e6) fresh |
| 5 | 35/F | Classical Hodgkin | ABVD, brentuximab, GDP, ICE, nivolumab, and everolimus | No | DL1 (120 e6) frozen |
| 7 | 46/F | NK/T-cell lymphoma, nasal type | Dex/etoposide/ifosfamide/carboplatin; XRT to soft palate and LN; pembrolizumab; ulixertinib | Yes | DL −1 (30 e6) frozen |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BM, bone marrow; CTCL, cutaneous T-cell lymphoma; cy, cyclophosphamide; DA, dose-adjusted; Dex, dexamethasone; DHAP, dexamethasone, cytarabine, cisplatin; DLI, donor leukocyte infusion; EPOCH, etoposide phosphate, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, doxorubicin hydrochloride (hydroxydaunorubicin); F, female; flu, fludarabine; GDP, gemcitabine, dexamethasone, cisplatin; Gem, gemcitabine; haplo, haploidentical; HD, high-dose; HGBCL, high-grade B-cell lymphoma; ICE, ifosfamide, carboplatin, etoposide phosphate; IT, intrathecal methotrexate; LN, lymph node; M, male; MMF, mycophenolate mofetil; MTX, methotrexate; Ox, oxaliplatin; PBSCT, peripheral blood stem cell transplant; R, rituximab; RIC, reduced intensity conditioning; TBI, total body irradiation; XRT, radiotherapy.